These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28883001)

  • 1. KDM4 Inhibition Targets Breast Cancer Stem-like Cells.
    Metzger E; Stepputtis SS; Strietz J; Preca BT; Urban S; Willmann D; Allen A; Zenk F; Iovino N; Bronsert P; Proske A; Follo M; Boerries M; Stickeler E; Xu J; Wallace MB; Stafford JA; Kanouni T; Maurer J; Schüle R
    Cancer Res; 2017 Nov; 77(21):5900-5912. PubMed ID: 28883001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
    Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells.
    Yan N; Xu L; Wu X; Zhang L; Fei X; Cao Y; Zhang F
    Exp Cell Res; 2017 Oct; 359(2):405-414. PubMed ID: 28823831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
    Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity.
    Xun J; Wang D; Shen L; Gong J; Gao R; Du L; Chang A; Song X; Xiang R; Tan X
    Oncotarget; 2017 Mar; 8(13):21918-21929. PubMed ID: 28423536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer.
    Meng Z; Liu Y; Wang J; Fan H; Fang H; Li S; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
    J Cell Physiol; 2020 Feb; 235(2):932-943. PubMed ID: 31236965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
    Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
    Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
    Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDM4B-regulated unfolded protein response as a therapeutic vulnerability in
    Wang W; Oguz G; Lee PL; Bao Y; Wang P; Terp MG; Ditzel HJ; Yu Q
    J Exp Med; 2018 Nov; 215(11):2833-2849. PubMed ID: 30266800
    [No Abstract]   [Full Text] [Related]  

  • 15. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.
    Iskit S; Lieftink C; Halonen P; Shahrabi A; Possik PA; Beijersbergen RL; Peeper DS
    Oncotarget; 2016 Jul; 7(28):42859-42872. PubMed ID: 27374095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
    Zheng Q; Fan H; Meng Z; Yuan L; Liu C; Peng Y; Zhao W; Wang L; Li J; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):897-904. PubMed ID: 30060056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
    Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
    Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy.
    Dutta I; Dieters-Castator D; Papatzimas JW; Medina A; Schueler J; Derksen DJ; Lajoie G; Postovit LM; Siegers GM
    Cancer Lett; 2021 Jan; 496():156-168. PubMed ID: 33045304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells.
    Jang GB; Hong IS; Kim RJ; Lee SY; Park SJ; Lee ES; Park JH; Yun CH; Chung JU; Lee KJ; Lee HY; Nam JS
    Cancer Res; 2015 Apr; 75(8):1691-702. PubMed ID: 25660951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.